Said Sebti

Company: VCU Massey Cancer Center

Job title: Co-Founder, Prescient Therapeutics & Associate Director of Basic Research

Seminars:

Latest Clinical Update on the Geranylygeranyltransferase-1 Inhibitor PTX-100 that Targets Pathway Downstream of RAS 1:45 pm

Evaluating how inhibition of Geranylgeranyltransferase 1 (GGT1) blocks prenylation of Rho and other GTPases and results in improved patient outcomes Understanding the CAAX peptidomimetic PTX-100’s potent pre-clinical anti-tumor activity Showcasing advancements in clinical trials that have shown promising results in the efficacy of PTX-100 for T-cell lymphomasRead more

day: Day Two Track B PM

RAS 101: Understanding the RAS Pathway & Its Oncogenic Mutations to Improve Drug Discovery & Design 9:01 am

The RAS/MAPK pathway is an extremely important signalling cascade that plays a major role in driving oncogenesis. It stretches from receptors on the cell membrane to transcription factors in the nucleus and is naturally robust to prevent disruption. Hence, to effectively target RAS and its surrounding molecules for effective cancer therapy, it is important to…Read more

day: Workshop A